Amersham wins US go-ahead
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MAGNUS GRIMOND
Amersham International, the health-care and life sciences group, has won approval to market its Myoview advanced heart imaging agent in the US. The news had been expected following an announcement in July, but it still sent the shares 15p higher to 850p yesterday.
The company said the US Food and Drug Administration had given the go- ahead to sell Myoview, a radiopharmaceutical agent used in heart imaging. It will be launched in the US next month, aimed at an estimated market worth pounds 140m, representing more than half the world-wide total for heart imaging of more than pounds 250m.
The proprietary kits for the preparation of the injectable medical isotope technetium will be marketed through the chain of 120 radiopharmacies and exclusive distributorships established by Amersham in the US last year. It received its first European licence in 1993 and is approved in all the big European markets and Japan.
.Bill Castell, chief executive, described the new agent as "a major step forward in non-invasive diagnosis of heart disease. It enables doctors to obtain clear heart images quickly and so operate an efficient and cost- effective service for the benefit of patient and hospital."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments